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Context: Clinical sequelae of androgen deficiency share common features with frailty. Evidence
supporting the role of androgens in the development of frailty is limited and conflicting.
Objective: To determine associations between male reproductive hormones and prospective
changes in frailty status.
Design/Setting: A 4.3-year prospective cohort study of community-dwelling men participating in
the European Male Ageing Study.
Participants: A total of 3369 men aged 40 to 79 from eight European centers.
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Intervention: None.
Main Outcome Measure: Frailty status was determined using frailty index (FI; n = 2278) and frailty
phenotype (FP; n = 1980).
Results:After adjusting for baseline frailty, age, center, and smoking, the risk ofworsening FI decreased
with higher testosterone (T), free T, and dihydrotestosterone (DHT) [percentage change (95% confi-
dence interval) in FI associatedwith 1 standard deviation higher hormone level: –3.0 (–5.9, –1.0) for total
T; –3.9 (–6.8, –2.0) for freeT; and –3.9 (–6.8, –2.0) forDHT].After further adjustment for bodymass index,
only free T remained a significant predictor of FI change. In fully adjusted models, higher luteinizing
hormone and follicle-stimulating hormone were positively related to worsening FI only in men ,60
years, and higher estradiol predicted lower likelihood of improving FP [odds ratio: 0.68 (0.52, 0.88)].
Conclusions: These prospective data support the hypothesis that higher androgen levels may protect
elderly men from worsening frailty. However, the causal nature of these relationships requires further
investigation.Whereas raisedgonadotropins inmen,60yearsmightbeanearlymarkerof frailty, the role
of estradiol in frailty needs further clarification. (J Clin EndocrinolMetab 103: 701–709, 2018)
F railty in the elderly describes a state of reduced ho-meostatic reserve and diminished resistance to external
and internal stressors, which is associated with adverse
outcomes such as disability, falls, and death (1, 2). With
rising life expectancy, frailty is increasingly recognized as
an important health care issue; much research has focused
on investigating its etiology and natural history to help
identify high-risk individuals and facilitate the develop-
ment of effective prevention and treatment strategies.
The pathophysiology of frailty is poorly understood, but
it has been linked with disruptions within a number of body
systems, including metabolic and inflammatory pathways
(3, 4). Both aging and frailty share common features in
relation to changes in body composition, muscle strength,
and physical function, which are accompanied by a parallel
decline in androgen levels. Therefore, dysregulation within
the hypothalamic-pituitary-gonadal axis has been suggested
to play a role in the development of frailty. The supporting
evidence, however, is rather limited. A number of studies
have investigated associations of testosterone (T) with pa-
rameters ofmuscle function andphysical performance (5, 6),
but relatively few, predominantly cross-sectional, studies
have focused on association between androgens and frailty
(7, 8), with conflicting results. Moreover, to date, frailty (as
opposed to muscle strength and physical performance) has
not been studied as a clinical outcome of interventional trials
of T replacement in older men.
We used the longitudinal data from the population-based
European Male Ageing Study (EMAS) to determine the
associations between hypothalamic-pituitary-gonadal
axis hormones and change in frailty status in middle-
aged and older men.
Methods
Subjects
Subjects included were participants in the EMAS as de-
scribed previously (9). Briefly, 3369 men aged 40 to 79 were
recruited between 2003 and 2005 from population-based
sampling frames in eight European centers: Florence (Italy),
Leuven (Belgium), Lodz (Poland), Malmo¨ (Sweden), Man-
chester (United Kingdom), Santiago de Compostela (Spain),
Szeged (Hungary), and Tartu (Estonia). The participants com-
pleted a series of clinical assessments andprovided a fasting blood
sample. Ethical approval was obtained in accordance with the
local requirements.
Participants were recontacted after a minimum of 4 years
(median, 4.3 years). Methods of data collection at follow-up
were largely identical to the baseline study. During follow-up,
193 (6%) men died and 440 (13%) were lost to follow-up.
Participants with self-reported history of testicular, adrenal,
and/or pituitary disease and/or the use of medications affecting
the functioning of the hypothalamic-pituitary-gonadal axis (an-
drogens, antiandrogens, 5-a reductase inhibitors, gonadotropin-
releasing hormone analogs, anabolic steroids, strong opioids, and
oral corticosteroids) were excluded.We did this for two reasons: 1)
because we were interested in the associations of physiological,
rather than pathological, differences in hormone levels with
changes in frailty and 2) because the diseases causing altered
hormone levels could have direct effects on frailty levels and
confound the relationship between hormone levels and changes
in frailty.
Assessments
All participants were asked questions concerning lifestyle,
general health, and comorbidities. The interviewer-assisted ques-
tionnaire included the Medical Outcomes Study 36-Item Short
Form Survey (10), the Physical Activity Scale for the Elderly (11),
Beck’s Depression Inventory (BDI) (12), and the International
Prostate Symptoms Score (13). Physical function was assessed by
Reuben’s Physical Performance Test (14) and the Tinetti Balance
and Postural Stability Index (15). The Rey-Osterrieth Complex
Figure Test (16), the Camden Topographical Recognition Mem-
ory Test (17), and the Digit-Symbol Substitution Test (18) were
used to assess the cognitive function. Anthropometric parameters
measured included height, weight, waist, mid upper arm, and calf
circumferences, and skinfold thicknesses.
Frailty measures
Frailty was characterized by the two commonly used ap-
proaches: frailty index (FI) and frailty phenotype (FP).
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The EMAS FI comprised 39 health deficits (symptoms, signs,
and functional and cognitive impairments) that accumulate with
age and are associated with adverse health outcomes. These
variables were derived from Medical Outcomes Study 36-Item
Short Form Survey and BDI questionnaires, physical perfor-
mance and cognitive test data, and self-reported comorbidities.
The EMAS FI was created using a standardized procedure (19)
and was calculated as the number of deficits present divided by
the maximum number of deficits possible. Binary variables
(coded as 0 or 1) indicated the absence or presence of a deficit,
and intermediate responses (e.g., sometimes/maybe) were coded
as 0.5. Continuous variables were dichotomized based on the
distribution of participants’ scores (cut points set at the worst
performing 10th centile) (Supplemental Table 1). Individuals
with .20% of deficit variables missing were excluded (Sup-
plemental Figs. 3 and 4).
EMAS FP was adapted from the five criteria used in the
Cardiovascular Health Study (2): sarcopenia, exhaustion,
slowness, weakness, and low activity. Variables used to con-
struct EMAS FP and population-specific frailty thresholds are
presented in Supplemental Table 2, alongside the original
Cardiovascular Health Study criteria. Individuals with three
or more criteria were classed as “frail,” those with one or two
as “prefrail,” and those with none as “robust” (Supplemental
Fig. 5). The EMAS FP has been shown to be predictive of ad-
verse health outcomes such as falls and death (20).
Reproductive hormones and SHBG
A fasting morning (before 10 AM) venous blood sample was
taken at baseline and follow-up. A validated gas (or liquid)
chromatography-mass spectrometry systemwas used to analyze
T [intra- and interassay coefficients of variation (CVs): 2.9%
and 3.4%], estradiol (E2; CVs: 3.5% and 3.7%), and dihy-
drotestosterone (DHT; CVs: 3.1% and 4.1%).
Luteinizing hormone (LH), follicle-stimulating hor-
mone (FSH), and sex hormone–binding globulin (SHBG) were
measured using the Modular E170 platform electro-
chemiluminescence immunoassay (Roche Diagnostics, Man-
nheim, Germany). Intra- and interassay CVs were 1.9% and
2.7% for LH, 0.9% and 1.9% for FSH, and 1.9% and 3.2%
for SHBG.
Free T (fT) levels were derived from total T, SHBG, and
albumin concentrations using Vermeulen’s formula (21).
Statistical analysis
Descriptive statistics were presented as mean 6 standard
deviation (SD) or n (%), and statistical significance of between-
group differences was assessed using analysis of variance.
FI models
In view of the right skewing of the FI variable, relationships
between individual endocrine predictors and FI at follow-up
(outcome) were assessed using negative binomial regression
modeling. The FI metric was calibrated as an additive 0- to
39-count scale, where “0” represented no deficits and “39”
represented the maximum deficits. Results were presented as
percentage change [95% confidence interval (CI)] in FI as-
sociated with a 1 SD higher baseline hormone level (negative
values indicating improving frailty and positive values in-
dicating worsening frailty during follow-up).
FP models
Change in frailty was defined using transitions in frailty
states between baseline and follow-up. The transitions con-
sidered were worsening frailty (robust or prefrail at baseline
progressing to prefrail or frail at follow-up; referent category:
persistent robust or persistent prefrail) and improving frailty
(prefrail or frail at baseline transitioning to robust or prefrail
state at follow-up; referent category: persistent frail or prefrail).
Logistic regression models determined relationships be-
tween individual predictors (hormones at baseline) and out-
come (transition in FP). Each hormone was represented by an
untransformed value and standardized as a z score [(raw score –
mean)/SD]. The results were displayed as odds ratios (ORs) with
95%CIs for a 4.3-year change in frailty status associated with a
1 SD difference in baseline hormone level.
Regression models were adjusted for baseline frailty status,
age, center, smoking (current or ex-/nonsmoker), and body
mass index (BMI) category (BMI , 25, 25 to 30, and $ 30).
These covariates were chosen because they correlated with
predictors and were not components of the FP or FI. Analyses in
which E2 was a predictor were adjusted for total T level—the
main precursor for E2 production in men.
All analyses were performed using STATA 13 SE software
(StataCorp LP, College Station, TX).
Results
Population characteristics
Of the 3369 men who participated in EMAS, 2278
men remained in the FI analysis and 1980 in the FP
analysis after exclusion of those with pituitary, testicu-
lar, or adrenal disease or use of medication affecting
hypothalamic-pituitary-gonadal axis (n = 312), missing
FI (n = 204), or FP (n = 502) data and failure to attend for
follow-up assessment (n = 575) (Supplemental Fig. 1).
Compared with the main analytical sample, men lost
to follow-up (n = 407) were older and had higher systolic
blood pressure and greater prevalence of smoking, de-
pression, diabetes, and frailty at baseline (Supplemental
Tables 3 and 4). This was also the case for the men who
died (n = 168), with addition of a higher creatinine and
waist-hip ratio in this group when compared with the
analytical sample (Supplemental Tables 3 and 4).
Baseline characteristics
Baseline clinical and hormonal characteristics of the
study participants are shown in Table 1. The men had
a mean 6 SD age of 58 6 11 years and a BMI of 28 6
4 kg/m2. Six percent were known to suffer from diabetes,
33% reported history of a cardiovascular disease (CVD),
and 21% had history of depression.
Differences in baseline parameters between frailty
transition groups are shown in Table 2. When com-
pared with men who remained robust or prefrail, those
whose frailty status deteriorated over follow-up (n = 426;
Supplemental Fig. 2) were older and had lower baseline
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BMI, but higher SHBG, LH, and FSH hormones and a
higher prevalence of diabetes and CVD. When compared
with men who remained persistently frail or prefrail, men
who experienced improvement in their frailty status (n =
196; Supplemental Fig. 2) were younger and had a lower
prevalence of CVD and lower baseline E2, SHBG, and
gonadotropin levels.
Hormonal predictors of worsening frailty
FI
In models adjusted for baseline frailty, age, center, and
smoking status, higher baseline levels of total T, free T
(fT), and DHTwere associated with a lower likelihood of
worsening FI (Table 3). After additional adjustment for
BMI, only fT remained a significant predictor of change
in FI. Higher baseline levels of SHBG, FSH, and LH were
associated with higher risk of worsening FI in models
adjusted for baseline FI (Table 3), but age adjustment
attenuated these relationships. Higher E2 levels predicted
worsening FI in a model adjusted for baseline FI, age,
center, and smoking; however, the statistical significance
was lost after additional adjustment for BMI (Table 3).
FP
In keeping with the FI results, higher baseline fT levels
were associated with a lower likelihood of worsening FP,
but this association became statistically nonsignificant
Table 1. Baseline Characteristics of the Study
Population
Baseline Parameter Mean 6 SD or n (%)
N 2278
Age, y 58 6 11
BMI, kg/m2 28 6 4
Smoking, n (%) 447 (20%)
Frequent alcohol, n (%) 546 (24%)
Systolic BP, mm Hg 145 6 20
Diastolic BP, mm Hg 87 6 12
PASE 206 6 87
Severe depression (BDI band 4–6), n (%) 69 (4%)
Mild depression (BDI band 2–3), n (%) 363 (17%)
CVD, n (%) 741 (33%)
Diabetes, n (%) 132 (6%)
Total T, nmol/L 16.9 6 6.0
fT, pmol/L 303.3 6 85.9
DHT, nmol/L 1.34 6 0.6
E2, pmol/L 73.6 6 24.6
SHBG, nmol/L 41.8 6 19.0
FSH, IU/L 8.0 6 8.4
LH, IU/L 6.0 6 4.0
Abbreviations: BP, blood pressure; N, number; PASE, Physical Activity
Scale for the Elderly.
Table 2. Baseline Parameters Stratified by Frailty Transition Group, as Assessed by FP Derived From the
Cardiovascular Health Study
Baseline Parameter Worsening Frailtya
Persistent Robust
and Persistent
Prefrail P Value
Improving
Frailtyb
Persistent Frail
and Persistent
Prefrail P Value
N 426 1352 196 236
Age, y 60 6 11 57 6 10 ,0.001 59 6 10 64 6 10 ,0.001
BMI, kg/m2 27.3 6 3.9 27.7 6 4.0 0.025 27.3 6 3.7 27.2 6 5.1 0.322
Smoking, n (%) 95 (22) 257 (19) 0.145 42 (22) 54 (23) 0.771
Frequent alcohol, n (%) 114 (27) 317 (24) 0.174 48 (25) 49 (21) 0.378
Systolic BP, mm Hg 145 6 20 145 6 20 0.910 144 6 21 147 6 22 0.158
Diastolic BP, mm Hg 87 6 11 88 6 12 0.297 89 6 13 86 6 12 0.063
PASE 192 6 80 217 6 86 ,0.001 158 6 93 145 6 94 0.124
Severe depression
(BDI band 4–6), n (%)
7 (2) 33 (3) 0.399 8 (5) 18 (11) 0.092
Mild depression
(BDI band 2–3), n (%)
77 (19) 194 (15) 0.064 47 (25) 65 (30) 0.280
CVD, n (%) 154 (36) 364 (29) 0.006 68 (35) 112 (48) 0.007
Diabetes, n (%) 32 (8) 63 (5) 0.024 10 (5) 22 (9) 0.097
Total T, nmol/L 17.2 6 6.1 17.0 6 6.0 0.363 16.4 6 5.8 17.3 6 6.5 0.179
fT, pmol/L 300.1 6 83.0 310.3 6 86.3 0.076 290.1 6 79.7 285.2 6 88.9 0.454
DHT, nmol/L 1.37 6 0.6 1.34 6 0.6 0.221 1.31 6 0.5 1.37 6 0.6 0.669
E2, pmol/L 74.5 6 25.8 73.8 6 24.0 0.668 69.8 6 21.3 77.5 6 29.8 0.010
SHBG, mmol/L 43.6 6 18.7 40.4 6 17.9 ,0.001 42.3 6 20.0 47.5 6 19.5 0.002
FSH, IU/L 8.4 6 7.8 7.3 6 6.9 0.003 8.0 6 8.9 9.9 6 12.1 0.017
LH, IU/L 6.1 6 3.6 5.6 6 3.5 0.010 5.7 6 3.9 6.9 6 5.5 0.005
Data are expressed as mean 6 SD for continuous variables or as number (percentage) for binary categorical variables. P values were calculated using
baseline parameters and using analysis of variance.
Abbreviations: BP, blood pressure; N, number; PASE, Physical Activity Scale for the Elderly.
aWorsening Frailty = robust or prefrail men at baseline progressing to prefrail or frail state at follow-up.
bImproving Frailty = prefrail or frail men at baseline transitioning to robust or prefrail state at follow-up.
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after adjusting for age (Table 4). Also in keeping with FI
data, higher baseline SHBG, LH, and FSH levels were
significantly associated with worsening FP in models
adjusted for baseline FP, but age adjustment, again, at-
tenuated these relationships. Baseline levels of T and
DHT were not related to worsening FP in any model.
Hormonal predictors of improving frailty
In prefrail or frail men, higher baseline levels of E2
were associated with a lower likelihood of improvement
in FP at follow-up in the fully adjusted model (Table 5).
Higher levels of SHBG and LH were associated with a
lower likelihood of improving FP, but these associations
became statistically nonsignificant after adjusting for age.
Levels of T, fT, and DHT were not related to FP im-
provement in any model.
Secondary analyses
In a secondary analysis, age modified the association
between gonadotropins andFI. In the fully adjustedmodels,
higher LH and FSH levels were related to worsening FI in
younger (,60 years old) but not older men [percentage
change in FI associated with 1 SD higher hormone level:
FSH, 10% (P = 0.002); LH, 9.6% (P = 0.003)].
In FP models, further adjustment for CVD, depression
(BDI score), and diabetes did not alter the relationship
between hormones and FP (Supplemental Tables 6 and
7); the association between E2 and improvement in FP
persisted [OR, 0.68 (0.51, 0.89); P = 0.005]. FI models
were not adjusted for CVD or diabetes because they are
components of FI.
Discussion
Main findings
These data describe the longitudinal associations of
reproductive hormone levels with changes in frailty status
in middle-aged and elderly men using two different frailty
models. Our main findings were (1) higher fT levels were
associated with a lower risk of worsening frailty status
with consistent directions of association using two dif-
ferent frailty constructs (FI and FP); (2) in age-adjusted
Table 3. Relationship Between Baseline Level of Endocrine Predictors and a 4-Year Percentage Change in FI
Models and Adjustments
Baseline
Parameter N
Model 1 Baseline Frailty
Model 2 Baseline
Frailty and Age
Model 3 Baseline Frailty, Age,
Center, Smoking
Model 4 Baseline Frailty, Age,
Center, Smoking, BMIc
% Changea 95% CI P Value % Changea 95% CI P Value % Changea 95% CI P Value % Changea 95% CI P Value
Total T 2262 23.0 24.9, –0.4 0.020 23.0 24.9, –0.5 0.015 23.0 25.9, –1.0 0.004 21.0 23.0, 1.0 0.354
fT 2257 28.6 210.5, –5.9 ,0.001 24.9 27.7, –3.0 ,0.001 23.9 26.8, –2.0 0.001 22.8 24.9, –0.3 0.030
DHT 2255 23.0 24.9, –0.6 0.013 23.9 26.8, –2.0 ,0.001 23.9 26.8, –2.0 ,0.001 22.0 24.0, 0.4 0.105
E2
b 2254 1.0 21.0, 3.0 0.389 2.0 21.0, 4.0 0.133 3.0 21.0, 5.1 0.027 1.0 21.0, 4.1 0.407
SHBG 2268 5.1 2.0, 7.2 ,0.001 0.4 22.0, 2.0 0.721 21.1 23.0, 1.3 0.368 1.0 21.0, 3.0 0.391
FSH 2267 5.1 3.0, 7.2 ,0.001 2.0 20.3, 4.0 0.091 1.0 21.0, 3.1 0.311 1.0 20.9, 3.0 0.274
LH 2266 4.1 2.0, 6.0 ,0.001 2.0 20.5, 7.0 0.113 1.0 21.0, 3.0 0.285 1.0 20.5, 3.0 0.138
Abbreviations: BMIc, BMI categories (,25, 25 to 30, $30); N, sample size.
aChange (percentage change/4 years) in FI per SD increase in hormone level. Negative percentage change means that the baseline hormone level is
associated with improvement of frailty status, and positive percentage change means that the hormone is associated with worsening frailty status.
bModels 2 to 4 additionally adjusted for baseline total T level.
Table 4. Multivariable-AdjustedOR (95%CI) forWorsening FP AssociatedWith Baseline Endocrine Predictors
Models and Adjustments
Baseline
Parameter N
Model 1 Baseline Frailty
Model 2 Baseline
Frailty and Age
Model 3 Baseline Frailty,
Age, Center, Smoking
Model 4 Baseline
Frailty, Age, Center,
Smoking, BMIc
OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
Total T 1766 1.04 0.93, 1.16 0.446 1.04 0.93, 1.16 0.520 1.08 0.96, 1.22 0.187 1.05 0.92, 1.18 0.474
fT 1760 0.86 0.77, 0.96 0.008 0.98 0.87, 1.1 0.702 1.03 0.91, 1.16 0.681 0.99 0.88, 0.04 0.979
DHT 1759 1.07 0.96, 1.19 0.213 1.03 0.92, 1.15 0.601 1.01 0.90, 1.14 0.822 0.96 0.85, 1.09 0.574
E2
a 1759 1.04 0.94, 1.16 0.435 0.99 0.87, 1.13 0.894 1.07 0.94, 1.23 0.300 1.11 0.97, 1.28 0.136
SHBG 1769 1.25 1.12, 1.39 ,0.001 1.08 0.96, 1.22 0.181 1.10 0.97, 1.24 0.144 1.06 0.94, 1.21 0.342
FSH 1768 1.21 1.09, 1.34 ,0.001 1.09 0.98, 1.22 0.123 1.11 0.99, 1.24 0.085 1.10 0.98, 1.24 0.094
LH 1767 1.20 1.08, 1.33 0.001 1.09 0.97, 1.22 0.132 1.08 0.96, 0.21 0.183 1.07 0.95, 1.20 0.257
Abbreviations: BMIc, BMI categories (,25, 25 to 30, $30); DM, diabetes mellitus; N, sample size.
aModels 2 to 4 additionally adjusted for baseline total T level.
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FI models, higher androgen levels (fT, T, and DHT)
remained significantly associated with improving frailty
status, suggesting that these relationships cannot be
explained by age-related differences in androgen levels;
(3) we provided evidence that frailty status was less likely
to improve in prefrail or frail men with higher baseline E2
levels; and (4) we showed that higher LH and FSH levels
were associated with worsening frailty status, but that
these relationships were largely explained by age-related
changes in these hormones, except in younger men.
We have previously shown that nonandrogenic ana-
bolic hormones such as IGF-1, IGFBP3, and vitamin D
were independently associated with change in frailty
status in middle-aged and older men (22). These two
complimentary reports enhance our understanding of a
relative role of the endocrine system in the development
of frailty and suggest that there may be multiple un-
derlying hormonal mechanisms involved in the patho-
genesis of frailty.
Prior studies
This is, to our knowledge, the first study to simulta-
neously use two common frailty measures to investigate
relationships between reproductive hormones and frailty.
Furthermore, whereas the majority of frailty studies have
been cross-sectional and have focused on elderly men, we
investigated frailty prospectively and included younger
men (40 to 59 years) to seek evidence that hormonal levels
might predispose to the development of onset of frailty.
Our results contrast with those of the Concord Health
and Ageing in Men Project (23), where 1166 men .70
years of age were followed for 2.1 years. The authors
found no association between baseline levels of T, fT,
DHT, SHBG, or gonadotropins and worsening frailty.
Moreover, the authors observed that lower levels of es-
trone (but not E2) were linked to prevalent and incident
frailty, but these findings were not confirmed when an
alternative measure of physical frailty (Study of Osteo-
porotic Fractures FI) was used (23). Methodological
differences (studying much older subjects, having shorter
follow-up, smaller sample size, and not adjusting for
baseline frailty status) may have contributed to differ-
ences compared with our study.
Cawthon et al. (8) reported longitudinal associations
between lower baseline bioavailable T, but not T, E2, or
SHBG, and a higher risk of frailty at 4.1 years in 1245
men aged .65 years participating in the Osteoporotic
Fractures in Men Study. Free T was not evaluated. Ad-
justment for a number of covariates, including age,
baseline frailty, BMI, comorbidities, education, smoking
status, marital status, and self-rated health, attenuated
this association. This loss of statistical significance could
perhaps be explained by covariates such as BMI being on
the causal pathway linking hormone levels to frailty.
However, in our study, fT and E2 remained significantly
predictive of frailty changes after covariate adjustments.
Therefore, overadjustment bias is unlikely to account
for the discrepant results. Notwithstanding the differ-
ences between bioavailable T and fT, it is possible that
sample size, the older age range (.65 years), and the
quartile modeling methodology used by Cawthon et al.
(8) may have mitigated against finding persistently sig-
nificant relationships.
By contrast, the Health in Men Study reported sta-
tistically significant associations between baseline levels
of immunoassayed T and calculated fT as well as LH and
frailty measured by the FRAIL scale in 1586 men aged 70
to 88 years followed for 6 years (7). Following adjustment
for age, BMI, smoking, diabetes, social support, and
impaired hearing and vision, only fT remained signifi-
cantly correlated with follow-up frailty status. These
findings are consistent with our present results. Our study
Table 5. Multivariable-Adjusted OR (95% CI) for Improving FP AssociatedWith Baseline Endocrine Predictors
Models and Adjustments
Baseline
Parameter N
Model 1 Baseline Frailty
Model 2 Baseline
Frailty and Age
Model 3 Baseline Frailty,
Age, Center, Smoking
Model 4 Baseline
Frailty, Age, Center,
Smoking, BMIc
OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
Total T 427 0.88 0.73, 1.06 0.181 0.85 0.69, 1.03 0.107 0.87 0.70, 1.07 0.183 0.87 0.69, 1.09 0.215
fT 427 1.09 0.90, 1.32 0.385 0.89 0.72, 1.10 0.290 0.89 0.71, 1.11 0.319 0.90 0.71, 1.13 0.349
DHT 428 0.91 0.75, 1.10 0.322 0.92 0.75, 1.12 0.413 0.94 0.76, 1.16 0.589 0.96 0.77, 1.21 0.764
E2
a 428 0.74 0.61, 0.89 0.002 0.81 0.64, 1.01 0.061 0.71 0.56, 0.91 0.008 0.68 0.52, 0.88 0.004
SHBG 429 0.76 0.63, 0.92 0.006 0.88 0.72, 1.08 0.223 0.90 0.72, 1.12 0.343 0.91 0.72, 1.15 0.446
FSH 429 0.88 0.76, 1.02 0.095 0.99 0.85, 1.15 0.906 1.02 0.88, 1.18 0.804 1.02 0.88, 1.19 0.791
LH 428 0.80 0.67, 0.96 0.018 0.91 0.76, 1.09 0.302 0.94 0.79, 1.12 0.484 0.94 0.79, 1.12 0.492
Abbreviations: BMIc, BMI categories (,25, 25 to 30, $30); DM, diabetes mellitus; N, sample size.
aModels 2 to 4 additionally adjusted for baseline total T level.
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adds important new data by assessing frailty through
objective and validated clinical assessments (not only
questionnaires) and by assessing participants using two
frailty measures in a larger and younger cohort that
captures earlier frailty transitions.
FI vs FP
Although we have shown significant associations
between reproductive hormones and frailty, it is im-
portant to note that relationships varied between the
two different constructs of frailty assessment. Covariates,
mainly age and BMI, confounded and attenuated the
hormone-frailty relationships, especially those between
hormones and FP. The discrepancies in the statistical
significance of the results could be explained by two
factors. First, the results might reflect differences in the
frailty definitions used in each model; whereas FP is a
measure of a physical frailty, FI is more holistic and in-
corporates physical, psychological, and cognitive factors.
Therefore, although higher androgens were related to
lower risk of worsening FI, the lack of significant asso-
ciations between androgens and worsening FP might
indicate that these hormones are more strongly predic-
tive of general health rather than musculoskeletal func-
tion. Alternatively, differences in statistical modeling of
“change” in frailty may explain the inconsistent associ-
ations with T and gonadotropins. FI, as a continuous
measure of frailty, offers a relatively greater sensitivity to
detect changes in frailty status compared with the less
frequent transitions between FP categories.
Potential pathophysiological mechanisms
Decline in muscle mass and function is thought to be
central to the development of frailty, and a large body
of evidence strongly supports the important anabolic
role of T on the skeletal muscle. T stimulates muscle fi-
ber hypertrophy through its action on muscle protein
synthesis and inhibition of degradation pathways (24);
nonetheless, the associations between T and measure-
ments of muscle strength and physical performance re-
main inconsistent (25, 26). Additionally, low T is thought
to be proinflammatory, which has been liked to frailty
development (27).
Although E2 is thought to be related to adiposity rather
than muscle function in men (28), negative associations
between E2 and muscle mass and strength have been
reported (29, 30). E2 might therefore be linked to frailty
through obesity or sarcopenic obesity, a feature of frailty
associated with poorer outcomes. We confirmed that
the effects of E2 on frailty were independent of T level.
Because E2 displays proinflammatory properties in
vivo (31), indirect effects of E2 on frailty via distur-
bance in inflammatory pathways need to be considered.
Nonetheless, further adjustment for baseline levels of
high-sensitivity C-reactive protein and leptin levels did
not change the associations between E2 and improving FP
[OR, 0.7 (0.52, 0.95); P = 0.022]. The potential patho-
physiological mechanisms linking E2 and frailty remain
poorly understood and require further investigation.
Strengths and limitations
This study has several strengths including: (1) use of a
well-defined longitudinal, community-based cohort; (2)
having a large sample size with adequate power to provide
conclusive results; (3) use of standardized methods in
central laboratories to assess hormone levels, including
mass spectrometry; (4) use of two well-validated frailty
models; and (5) the inclusion of men under 65 years of age
who have not been studied previously in this context.
We acknowledge some limitations: (1) The response
rate for participation was 41%. Although this is com-
parable to other large epidemiological studies, the oc-
currence of frailty in the study might have been over-
or underestimated through selection. (2) One hundred
ninety-three men died during follow-up, and 440 men
were lost to follow-up. Therefore, the true incidence of
frailty has probably been underestimated. Because this
would bias the results toward the null, the reported
strength of our associations are likely to be conservative.
(3) Our analysis is based on the results of single hormone
measurements, which do not capture pulsatile hormone
variation and could attenuate regression coefficients to-
ward the null through regression dilution bias.
Conclusion
In summary, these prospective data provide important
insight into the potential role of reproductive hormones
in the development, progression, and recovery of frailty
in aging men. The results cannot confirm a causal re-
lationship between androgen status and progression of
frailty, but the clear associations shown here make a
strong case for definitive, large interventional trials of T
therapy in frail men to determine whether such treatment
would be beneficial. We show that raised gonadotropins
in men,60 years old might be an early marker of frailty
and accelerated aging and suggest that the role of E2 in
frailty requires further investigation.
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